DePuy Spine fact sheet

company overview

 

  • DePuy Spine, a Johnson & Johnson company, is a division of DePuy, Inc., the world’s leading orthopaedic company

  • Second largest spine company in the world offering devices and solutions for fixation and fusion, motion preservation,     minimally invasive spine surgery and biologics

  • Worldwide headquarters in Raynham, Massachusetts; approximately 440 employees in the U.S. and 1,100 worldwide

  • Manufacturing plants located in Massachusetts, California, Ireland, Germany, and Switzerland

  • DePuy Spine products and solutions are used by surgeons in over 54 countries

 

major milestones

 

  1. 1993 - DePuy enters into spinal implant market by forming a joint venture with Biedermann Motech, a German manufacturer in           the spinal market. The new company is named DePuy Motech, Inc.
  2. 1998 - DePuy Motech, Inc. acquires AcroMed Corp., the developer of the first pedicle screw fixation system, and changes its           name to DePuy AcroMed, Inc.
  3. 1998 - Johnson & Johnson acquires DePuy AcroMed, Inc.
  4. 2003 - To signify a pivotal point in the history of its spine division and reflect its mission and growing position in the DePuy           franchise, the DePuy AcroMed division of DePuy, Inc., is renamed DePuy Spine, Inc.
  5. 2004 - The CHARITÉ® Artificial Disc is the first artificial disc to be approved by the U.S. Food & Drug Administration (FDA) as a           surgical treatment for patients suffering with single-level degenerative disc disease (DDD) at levels L4–5 or L5–S1 in the           spine
  6. 2004 - DePuy Spine introduces the EXPEDIUM™ Spine System, designed to offer specific solutions for the unique needs of           individuals with spinal injuries ranging from scoliosis to degenerative disc disease
  7. 2007 - DePuy Spine introduces eight new products to the market, including AEGIS™, the company’s first anterior plate system           designed to treat degenerative conditions of the lumbar spine

 

The CHARITÉ® Artificial Disc is indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at one level from L4-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients should have no more than 3mm of spondylolisthesis at the involved level. Patients receiving the CHARITÉ Artificial Disc should have failed at least six months of conservative treatment prior to implantation of the CHARITÉ Artificial Disc.